Join Aitia at the GAP-Net Site Optimization Conference in New Orleans, Louisiana on Feb 28 – March 1, 2024. This conference is exclusively focused on enhancing clinical trials, bringing together clinical research leaders and executive teams from prominent Alzheimer’s and Parkinson’s disease clinical trial sites across North America, along with pharmaceutical sponsors, CROs, and other industry partners dedicated to accelerating clinical research and shaping the Alzheimer’s R&D landscape.
We at Aitia, have been engaged in accelerating AI-driven discoveries in Alzheimer’s Disease. We initiated dedicated internal research efforts and is working closely with strategic data partners including Alzheimer’s Disease Neuroimaging Initiative (ADNI), Accelerating Medicines Partnership (AMP-AD), ANMerge, and Global Alzheimer’s Platform Foundation (GAP) to create Gemini Digital Twins that unravel the complex circuitry of the disease, with the ultimate goal of providing new hope to all who are impacted by this debilitating disease.
At CTAD 2023, we presented a poster on our recent study focused on results from Alzheimer’s Digital Twins derived from the GAP Bio-Hermes study, the largest AD trial of its kind evaluating biomarkers, surrogate markers, and cognitive tests and prioritizing diversity in the study protocol. Aitia Gemini Digital Twins have yielded new levels of predictive accuracy of PET positivity across different ethnoracial groups as well as various disease stages. These models may result in a cost-effective and convenient approach to address the high screen failure rate in clinical trial recruitment that currently plagues Alzheimer’s clinical trials. You can check the poster presented at CTAD here.
Fill out the contact form below and meet our team at the GAP-Net Site Optimization Conference this year to learn more about our groundbreaking work.